Volume 22, Issue 2 (6-2019)
J Arak Uni Med Sci 2019, 22(2): 115-120 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Moini A, Mehraban L. Pulmonary Mucormycosis: A Case Report. J Arak Uni Med Sci 2019; 22 (2) :115-120
URL: http://jams.arakmu.ac.ir/article-1-5864-en.html
URL: http://jams.arakmu.ac.ir/article-1-5864-en.html
1- Department of Internal Medicine , Arak University of Medical Sciences, Arak, Iran. , moini_latif@yahoo.com
2- Department of Internal Medicine , Arak University of Medical Sciences, Arak, Iran.
2- Department of Internal Medicine , Arak University of Medical Sciences, Arak, Iran.
Abstract: (13706 Views)
Background and Aim: Mucormycosis represents a group of life threatening infections caused by fungi of the order mucorales. Mucormycosis results in higher rates of morbidity and mortality than many other infections. A high index of suspicion and considering risky factors are critical for diagnosis and early initiation of therapy is necessary to optimize outcomes. In this paper, we report a woman with pulmonary mucormycosis.
Case Report: A 47-year old woman with a history of uncontrolled diabetes presented with cough, hemoptysis, dyspnea and dysphagia from 3 weeks ago. On physical examination, course crackles, generalized wheezing and stridor were found along with fever. Laboratory testing demonstrated a high-titer ESR, CRP3+ and leukocytosis. The ENT examination revealed a mild erythema of the vocal cords. An initial chest-x-ray was compatible with a pulmonary infiltration in the right middle lobe. Ct-scan of the sinuses was unremarkable. Bronchoscopy findings and lung biopsy was consistent fibrinoleukocytic exudates with extensive necrosis and broad hyphae and was reported fungal infection in favor of mucormycosis. She was eventually treated with amphotericin B.
Ethical Considerations: This study with research ethics code IR.ARAKMU.REC.1398.48 has been approved by research ethics committee at Arak University of Medical Sciences.
Conclusion: Mucormycosis has high mortality in diabetic patients and has even higher rates in uncontrolled diabetics. Therefore, due to underestimation and undertreatment of the condition, mucormycosis must be considered in diabetics underestimate pneumonia.
Case Report: A 47-year old woman with a history of uncontrolled diabetes presented with cough, hemoptysis, dyspnea and dysphagia from 3 weeks ago. On physical examination, course crackles, generalized wheezing and stridor were found along with fever. Laboratory testing demonstrated a high-titer ESR, CRP3+ and leukocytosis. The ENT examination revealed a mild erythema of the vocal cords. An initial chest-x-ray was compatible with a pulmonary infiltration in the right middle lobe. Ct-scan of the sinuses was unremarkable. Bronchoscopy findings and lung biopsy was consistent fibrinoleukocytic exudates with extensive necrosis and broad hyphae and was reported fungal infection in favor of mucormycosis. She was eventually treated with amphotericin B.
Ethical Considerations: This study with research ethics code IR.ARAKMU.REC.1398.48 has been approved by research ethics committee at Arak University of Medical Sciences.
Conclusion: Mucormycosis has high mortality in diabetic patients and has even higher rates in uncontrolled diabetics. Therefore, due to underestimation and undertreatment of the condition, mucormycosis must be considered in diabetics underestimate pneumonia.
References
1. Francis Y. W. Lee, Sherif B. Mossad, ; Karim A. Adal . Pulmonary MucormycosisThe Last 30 Years, Arch Intern Med. 1999; 159(12):1301-1309. doi:10.1001/archinte.159.12.1301.
2. Yamin HS, Alastal AY, Bakri I. Pulmonary Mucormycosis Over 130 Years: A Case Report and Literature Review. Turk Thorac J. 2017; 18(1):1-5.
3. Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clil Microbiol Rev. 2005; 18(3): 556-569.
4. Javadi M, Mohammadi Sh, Daneshi A. Rhinorbital cerebral mucormycosis: case Report. RJMS. 2001; 26(8): 397-404.
5. Mohamadi G, Kavosi A, Raziani Y, Parvinian nasab A.M. Rhinocerebral mucormycosis and treatment: Report of two cases. J Neyshabur Univ Med Sci .2014, 2(2): 10-13.
6. Taziki M , Khodabakhshi B , Tafreshi M, Golsha R, Rhinocerebral Mucormycosis: A Series of Six cases in Gorgan, J Mazandaran Univ Med Sci .2015; 25(124): 236-243.
7. Dounia Bitar, Dieter Van Cauteren, Fanny Lanternier, Eric Dannaoui, Didier Che, Francoise Dromer, Jean-Claude Desenclos, and Olivier Lortholary, Increasing Incidence of Zygomycosis (Mucormycosis), France, 1997–2006, Emerg Infect Dis. 2009; 15(9): 1395–1401. doi: 10.3201/eid1509.090334.
8. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL,et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005; 41(5):634-53.
9. Dimitrios P. Kontoyiannis, Decrease in the Number of Reported Cases of Zygomycosis among Patients with Diabetes Mellitus: A Hypothesis, Clinical Infectious Diseases, Volume 44, Issue 8, 15 2007, 1089–1090, [DOI:10.1086/512817.]
10. Kwan LP, Choy CB, Chan TM, et al. Successful treatment of pulmonary rhizopus infection with surgical resection and posaconazole in a renal transplant recipient. Nephrology (Carlton) 2013; 18:74–5. [DOI:10.1111/j.1440-1797.2012.01616.x. [PubMed].]
11. Dimitrios P. Kontoyiannis and Russell E. Lewis, How I treat mucormycosis, Blood 2011: blood-2011-03-316430; doi: [DOI:10.1182/blood-2011-03-316430.]
12. Fernandez JF, Maselli DJ, Simpson T, Restrepo MI. Pulmonary mucormycosis: what is the best strategy for therapy? Respir Care. 2013; 58: 60–3. [PMC free article] [PubMed].
13. Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg. 1994;57(4):1044-50.
14. Brown RB, Johnson JH, Kessinger JM, Sealy WC. Bronchovascular mucormycosis in the diabetic: an urgent surgical problem.Ann Thorac Surg. 1992; 53(5):854-5.
15. Alfageme I, Reina A, Gallego J, et al. Endobronchial instillations of amphotericin B: complementary treatment for pulmonary mucormycosis. J Bronchology Interv Pulmonol. 2009; 16: 214–5. [DOI:10.1097/LBR.0b013e3181aa2583. [PubMed].]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
